Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citigroup Inc. stock logo
C
Citigroup
$125.19
+0.3%
$120.40
$71.65
$135.29
$213.51B1.1413.88 million shs6.83 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,041.89
+2.3%
$940.69
$623.78
$1,133.95
$981.19B0.483.19 million shs2.70 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.38
-1.5%
$40.05
$35.12
$81.44
$198.17B0.7721.35 million shs11.60 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citigroup Inc. stock logo
C
Citigroup
+4.03%+0.56%-6.12%+7.98%+64.57%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.16%+0.11%+10.37%-0.69%+36.25%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.88%-4.36%+11.41%-7.00%-33.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Citigroup Inc. stock logo
C
Citigroup
$125.19
+0.3%
$120.40
$71.65
$135.29
$213.51B1.1413.88 million shs6.83 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,041.89
+2.3%
$940.69
$623.78
$1,133.95
$981.19B0.483.19 million shs2.70 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$44.38
-1.5%
$40.05
$35.12
$81.44
$198.17B0.7721.35 million shs11.60 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Citigroup Inc. stock logo
C
Citigroup
+4.03%+0.56%-6.12%+7.98%+64.57%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.16%+0.11%+10.37%-0.69%+36.25%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.88%-4.36%+11.41%-7.00%-33.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Citigroup Inc. stock logo
C
Citigroup
2.80
Moderate Buy$137.629.93% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.87
Moderate Buy$1,219.2617.02% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.13
Hold$65.5647.72% Upside

Current Analyst Ratings Breakdown

Latest LLY, C, and NVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,350.00
5/21/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform
5/19/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B)Buy (B-)
5/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingNeutral
5/8/2026
Citigroup Inc. stock logo
C
Citigroup
Reiterated RatingOutperform$145.00
5/8/2026
Citigroup Inc. stock logo
C
Citigroup
Boost Price TargetOutperform$140.00 ➝ $153.00
5/7/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price Target$880.00 ➝ $900.00
5/5/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,183.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B-)Buy (B)
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,325.00
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,350.00 ➝ $1,400.00
(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Citigroup Inc. stock logo
C
Citigroup
$88.28B2.42$12.39 per share10.10$113.17 per share1.11
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B15.05$25.64 per share40.63$33.13 per share31.45
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.23$4.70 per share9.45$7.12 per share6.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Citigroup Inc. stock logo
C
Citigroup
$14.31B$8.0715.5110.100.549.35%9.19%0.67%7/14/2026 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$28.1537.0123.561.1134.98%105.77%23.76%8/5/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.2610.4212.863.9437.23%63.31%22.19%8/5/2026 (Estimated)

Latest LLY, C, and NVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion
4/30/2026Q1 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.97$8.55+$1.58$8.26$17.82 billion$19.80 billion
4/14/2026Q1 2026
Citigroup Inc. stock logo
C
Citigroup
$2.63$3.06+$0.43$3.06$22.96 billion$24.63 billion
3/31/2026Q1 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$1.0270N/A$1.69N/A$10.85 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Citigroup Inc. stock logo
C
Citigroup
$2.401.92%+2.61%29.74%2 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.66%+15.18%24.58%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.753.94%+21.74%41.08%N/A

Latest LLY, C, and NVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/4/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.69%5/15/20265/15/20266/10/2026
4/2/2026
Citigroup Inc. stock logo
C
Citigroup
quarterly$0.601.91%5/4/20265/4/20265/22/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Citigroup Inc. stock logo
C
Citigroup
1.59
0.99
0.99
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.26
1.50
1.10
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56

Institutional Ownership

CompanyInstitutional Ownership
Citigroup Inc. stock logo
C
Citigroup
71.72%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Citigroup Inc. stock logo
C
Citigroup
0.11%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Citigroup Inc. stock logo
C
Citigroup
226,0001.71 billion1.70 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000941.74 million940.42 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Deutsche Bank Remains a Hold on Novo Nordisk (0QIU)
Could Viking Therapeutics Be the Next Eli Lilly?
Best Weight Loss Drug Stocks to Buy in 2026
Denmark GDP Jumps 1.9% as Pharma Sector Drives Growth

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Citigroup stock logo

Citigroup NYSE:C

$125.18 +0.37 (+0.29%)
Closing price 03:59 PM Eastern
Extended Trading
$124.78 -0.40 (-0.32%)
As of 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citigroup Inc., a diversified financial service holding company, provides various financial product and services to consumers, corporations, governments, and institutions worldwide. It operates through five segments: Services, Markets, Banking, U.S. Personal Banking, and Wealth. The Services segment includes Treasury and Trade Solutions, which provides cash management, trade, and working capital solutions to multinational corporations, financial institutions, and public sector organizations; and Securities Services, such as cross-border support for clients, local market expertise, post-trade technologies, data solutions, and various securities services solutions. The Markets segment offers sales and trading services for equities, foreign exchange, rates, spread products, and commodities to corporate, institutional, and public sector clients; and market-making services, including asset classes, risk management solutions, financing, prime brokerage, research, securities clearing, and settlement. The banking segment includes investment banking; advisory services related to mergers and acquisitions, divestitures, restructurings, and corporate defense activities; and corporate lending, which includes corporate and commercial banking. The U.S. Personal Banking segment provides co-branded cards and retail banking services. The Wealth segment provides financial services to high-net-worth clients through banking, lending, mortgages, investment, custody, and trust product offerings; and to professional industries, including law firms, consulting groups, accounting, and asset management. The company was founded in 1812 and is headquartered in New York, New York.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,041.89 +23.02 (+2.26%)
Closing price 03:59 PM Eastern
Extended Trading
$1,042.82 +0.93 (+0.09%)
As of 06:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$44.38 -0.69 (-1.52%)
Closing price 03:59 PM Eastern
Extended Trading
$44.43 +0.05 (+0.11%)
As of 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.